Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis |
| |
| Affiliation: | 1. Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus and Universitat Autònoma de Barcelona, Barcelona, Spain;2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain;1. Laboratorio de Virología Molecular, CMBC, IVIC, Apdo 20632, 1020A Caracas, Venezuela;2. INSERM U1052, CNRS 5286, Univ Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France;1. Department of Medical Oncology, Besançon University Hospital, 3, boulevard Alexandre-Fleming, 25030 Besançon, France;2. Department of Medical Oncology, Curie Institute, Versailles Saint-Quentin University, 35, rue Dailly, 92210 Saint-Cloud, France;1. Department of Digestive, Hepato-Biliary and Pancreatic Surgery and Liver Transplantation, AP–HP, Pitié-Salpêtrière Hospital, Paris, France;2. Department of Hepato-Biliary and Pancreatic Surgery and Liver Transplantation, Haut Lévêque Hospital, CHU de Bordeaux, Bordeaux, France;3. Sorbonne Université, UMPC Université Paris 6, Paris, France;4. Centre de Recherche de Saint-Antoine (CRSA), INSERM, UMRS-938, Paris, France;5. Department of Hepatology, AP–HP Pitié-Salpêtrière Hospital, Paris, France;1. Health Management Institute, Xinjiang Medical University, China;2. Public Health School of Xinjiang Medical University, China;3. Department of Microrepair and Reconstruction, the First Affiliated Hospital of Xinjiang Medical University, China;4. Department of abdominal ultrasound, the First Affiliated Hospital of Xinjiang Medical University, China;5. Department of Endocrinology, the First Affiliated Hospital of Xinjiang Medical University, China |
| |
| Abstract: | |
| |
| Keywords: | Immune checkpoint therapy Advanced hepatocellular carcinoma Adverse events AEs" },{" #name" :" keyword" ," $" :{" id" :" kw0025" }," $$" :[{" #name" :" text" ," _" :" Adverse Events AHCC" },{" #name" :" keyword" ," $" :{" id" :" kw0035" }," $$" :[{" #name" :" text" ," _" :" Advanced Hepatocellular Carcinoma AST" },{" #name" :" keyword" ," $" :{" id" :" kw0045" }," $$" :[{" #name" :" text" ," _" :" Aspartate Aminotransferase ALT" },{" #name" :" keyword" ," $" :{" id" :" kw0055" }," $$" :[{" #name" :" text" ," _" :" Alanine Aminotransferase CTLA-4" },{" #name" :" keyword" ," $" :{" id" :" kw0065" }," $$" :[{" #name" :" text" ," _" :" Cytotoxic T-lymphocyte Antigen 4 CTCAE" },{" #name" :" keyword" ," $" :{" id" :" kw0075" }," $$" :[{" #name" :" text" ," _" :" Common Terminology Criteria for Adverse Events FAEs" },{" #name" :" keyword" ," $" :{" id" :" kw0085" }," $$" :[{" #name" :" text" ," _" :" Fatal Adverse Events HCC" },{" #name" :" keyword" ," $" :{" id" :" kw0095" }," $$" :[{" #name" :" text" ," _" :" Hepatocellular Carcinoma NR" },{" #name" :" keyword" ," $" :{" id" :" kw0105" }," $$" :[{" #name" :" text" ," _" :" Not Reported NOS" },{" #name" :" keyword" ," $" :{" id" :" kw0115" }," $$" :[{" #name" :" text" ," _" :" Newcastle–Ottawa Scale 95% CIs" },{" #name" :" keyword" ," $" :{" id" :" kw0125" }," $$" :[{" #name" :" text" ," _" :" 95% Confidence Intervals OS" },{" #name" :" keyword" ," $" :{" id" :" kw0135" }," $$" :[{" #name" :" text" ," _" :" Overall Survival PY" },{" #name" :" keyword" ," $" :{" id" :" kw0145" }," $$" :[{" #name" :" text" ," _" :" Person-Year PFS" },{" #name" :" keyword" ," $" :{" id" :" kw0155" }," $$" :[{" #name" :" text" ," _" :" Progression-Free Survival PD-L1" },{" #name" :" keyword" ," $" :{" id" :" kw0165" }," $$" :[{" #name" :" text" ," _" :" Programmed Cell Death-ligand 1 PD-1" },{" #name" :" keyword" ," $" :{" id" :" kw0175" }," $$" :[{" #name" :" text" ," _" :" Programmed Cell Death Protein-1 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
